[{"id":"963274c2-ef1a-43d9-bccd-99053c776187","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599634","created_at":"2023-06-02T17:05:43.963Z","updated_at":"2025-02-25T16:53:20.802Z","phase":"Phase 1","brief_title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","source_id_and_acronym":"NCT04599634","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 06/20/2024","study_completion_date":" 06/20/2024","last_update_posted":"2025-02-04"},{"id":"05e37930-8cbd-43e9-89a2-63149b04e396","acronym":"","url":"https://clinicaltrials.gov/study/NCT03913559","created_at":"2021-01-18T19:15:34.393Z","updated_at":"2024-07-02T16:35:08.745Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","source_id_and_acronym":"NCT03913559","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-19"},{"id":"6aea670a-703a-4441-a9ff-cf2cf5b73ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04479267","created_at":"2021-01-18T21:30:41.002Z","updated_at":"2024-07-02T16:35:13.759Z","phase":"Phase 2","brief_title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","source_id_and_acronym":"NCT04479267","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/21/2020","start_date":" 08/21/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-03-20"},{"id":"be4f16e6-3542-42a3-8f39-b8e294f6cbed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305145","created_at":"2021-01-18T20:52:42.915Z","updated_at":"2024-07-02T16:35:14.376Z","phase":"Phase 2","brief_title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","source_id_and_acronym":"NCT04305145","lead_sponsor":"Massachusetts General Hospital","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-03-15"},{"id":"28c2e848-0f11-4013-9ceb-12f7e4e707d8","acronym":"ZUMA-7","url":"https://clinicaltrials.gov/study/NCT03391466","created_at":"2021-01-18T16:44:14.245Z","updated_at":"2024-07-02T16:35:15.970Z","phase":"Phase 3","brief_title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03391466 - ZUMA-7","lead_sponsor":"Kite, A Gilead Company","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • cyclophosphamide • oxaliplatin • Yescarta (axicabtagene ciloleucel) • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 359","initiation":"Initiation: 01/25/2018","start_date":" 01/25/2018","primary_txt":" Primary completion: 03/18/2021","primary_completion_date":" 03/18/2021","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-07"},{"id":"e8ed0c73-52de-4b1c-b080-5d8e96a4f341","acronym":"BRESELIBET","url":"https://clinicaltrials.gov/study/NCT04378647","created_at":"2021-01-18T21:08:51.476Z","updated_at":"2024-07-02T16:35:17.605Z","phase":"Phase 2","brief_title":"BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant","source_id_and_acronym":"NCT04378647 - BRESELIBET","lead_sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Adcetris (brentuximab vedotin) • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-02-26"},{"id":"e0422d9b-926f-4a65-aa54-3c0f6660d85a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00882895","created_at":"2021-01-18T03:22:39.839Z","updated_at":"2024-07-02T16:35:22.591Z","phase":"Phase 2","brief_title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00882895","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • methylprednisolone sodium succinate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/05/2009","start_date":" 05/05/2009","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-01-23"},{"id":"147be330-c08c-4ed4-9d27-7e0355b313e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02661035","created_at":"2021-01-18T12:57:57.203Z","updated_at":"2024-07-02T16:35:36.183Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC for Hematological Diseases","source_id_and_acronym":"NCT02661035","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A • IKZF1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 03/09/2017","start_date":" 03/09/2017","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 05/29/2023","study_completion_date":" 05/29/2023","last_update_posted":"2023-09-21"},{"id":"94fe4903-a2c9-42e8-862b-770fa6d33088","acronym":"I-HEP","url":"https://clinicaltrials.gov/study/NCT04810156","created_at":"2021-03-22T11:52:24.698Z","updated_at":"2025-02-25T14:02:17.911Z","phase":"Phase 2","brief_title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","source_id_and_acronym":"NCT04810156 - I-HEP","lead_sponsor":"Inge Marie Svane","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prednisone • methylprednisolone sodium succinate • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/07/2025","primary_completion_date":" 04/07/2025","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2022-12-14"},{"id":"a6865147-d492-4b7c-ab7e-c32c506cfa4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02500550","created_at":"2022-01-21T22:01:20.459Z","updated_at":"2024-07-02T16:36:30.087Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor","source_id_and_acronym":"NCT02500550","lead_sponsor":"Kiadis Pharma","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rhitol (allodepleted T-cell immunotherapeutics) • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 10/09/2015","start_date":" 10/09/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 12/17/2018","study_completion_date":" 12/17/2018","last_update_posted":"2021-05-18"},{"id":"65ef933e-5bd4-4594-99fd-d1500caca8a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00068523","created_at":"2021-01-18T00:10:09.988Z","updated_at":"2024-07-02T16:36:42.765Z","phase":"","brief_title":"Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT00068523","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" CCND1 • HLA-B","pipe":"","alterations":" ","tags":["CCND1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • cyclophosphamide intravenous • methylprednisolone oral • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2003","start_date":" 06/01/2003","primary_txt":" Primary completion: 03/01/2004","primary_completion_date":" 03/01/2004","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-27"},{"id":"7fe340c9-513c-406f-b823-d137d2a40da4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00553202","created_at":"2021-01-18T02:00:55.280Z","updated_at":"2024-07-02T16:36:45.945Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia","source_id_and_acronym":"NCT00553202","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 03/31/2020","study_completion_date":" 03/31/2020","last_update_posted":"2020-04-16"},{"id":"a17ffe57-fe51-4cfc-be1c-843d4dbb12e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00185692","created_at":"2021-01-18T00:37:49.022Z","updated_at":"2024-07-02T16:36:52.917Z","phase":"Phase 2","brief_title":"Allogeneic Transplantation From Related Haploidentical Donors","source_id_and_acronym":"NCT00185692","lead_sponsor":"Stanford University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporine • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2019-12-04"},{"id":"f098b0c9-04d9-4c7d-8399-1bb7e2d2b40a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01093586","created_at":"2021-01-18T04:19:20.928Z","updated_at":"2025-02-25T16:23:22.361Z","phase":"Phase 2","brief_title":"Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","source_id_and_acronym":"NCT01093586","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" KMT2A • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methylprednisolone acetate • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2019-01-23"},{"id":"ced9bc0e-29ae-4948-8e4a-05fa8abeddb9","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT01406756","created_at":"2021-01-18T05:47:00.296Z","updated_at":"2024-07-02T16:37:15.546Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01406756 - AALL1131","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • dexamethasone • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methylprednisolone sodium succinate"],"overall_status":"Recruiting","enrollment":" Enrollment 4895","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-13"},{"id":"4f93368f-4a04-4dff-8a96-d6f0cd7118ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT00899847","created_at":"2021-01-18T03:27:43.630Z","updated_at":"2024-07-02T16:37:16.977Z","phase":"Phase 2","brief_title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI \u0026 ATG","source_id_and_acronym":"NCT00899847","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • cyclosporin A microemulsion • Neupogen (filgrastim) • cyclophosphamide intravenous • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2017-10-20"}]